Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Short term Debt: 2011-2024

Historic Short term Debt for Ani Pharmaceuticals (ANIP) over the last 11 years, with Dec 2024 value amounting to $9.2 million.

  • Ani Pharmaceuticals' Short term Debt rose 113.10% to $15.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.2 million, marking a year-over-year increase of 113.10%. This contributed to the annual value of $9.2 million for FY2024, which is 25.22% down from last year.
  • Per Ani Pharmaceuticals' latest filing, its Short term Debt stood at $9.2 million for FY2024, which was down 25.22% from $12.3 million recorded in FY2023.
  • Over the past 5 years, Ani Pharmaceuticals' Short term Debt peaked at $13.2 million during FY2020, and registered a low of $850,000 during FY2021.
  • In the last 3 years, Ani Pharmaceuticals' Short term Debt had a median value of $9.2 million in 2024 and averaged $7.4 million.
  • Its Short term Debt has fluctuated over the past 5 years, first crashed by 93.58% in 2021, then spiked by 1,343.06% in 2023.
  • Ani Pharmaceuticals' Short term Debt (Yearly) stood at $13.2 million in 2020, then tumbled by 93.58% to $850,000 in 2021, then remained steady at $850,000 in 2022, then skyrocketed by 1,343.06% to $12.3 million in 2023, then dropped by 25.22% to $9.2 million in 2024.